SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 26.79 |
| Enterprise Value ($M) | 23.05 |
| Book Value ($M) | 19.12 |
| Book Value / Share | 3.57 |
| Price / Book | 1.40 |
| NCAV ($M) | 18.92 |
| NCAV / Share | 3.54 |
| Price / NCAV | 1.42 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.21 |
| Return on Assets (ROA) | -0.16 |
| Return on Equity (ROE) | -0.18 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 12.97 |
| Current Ratio | 12.97 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 20.50 |
| Assets | 20.70 |
| Liabilities | 1.58 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 27,306 | 121,444 | 22.48 | |
| 5,000 | 18,577 | 26.92 | |
| 2,750 | 10,519 | 26.14 | |
| 2,080 | 12,541 | 16.59 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| LGVN – Longeveron Inc. | LIPO – Lipella Pharmaceuticals Inc. |
| LIXT – Lixte Biotechnology Holdings, Inc. | LPTX – Leap Therapeutics, Inc. |
| LQDA – Liquidia Corporation |